~~<i id='07EEC0B1E1'><strike id='07EEC0B1E1'><tt id='07EEC0B1E1'><pre id='07EEC0B1E1'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

leisure time

author：explore 2025-09-09 19:27:51 - browse：9691

Adam's take main illustration — Molly Ferguson/STAT

Shares of Apellis Pharmaceuticals are rebounding, driven by a growing belief among some investors that the serious safety issue that has derailed Syfovre, the company’s eye disease treatment, is receding.

Declaring the crisis over is premature, but that could change with more uneventful weeks. Apellis has been a takeout target before, and may be again, at an acquisition price nearly twice its current market value.

Apellis shares rose 32% last week, with most of the gains coming Friday on heavy trading volume. The reason: There have been no new cases of retinal occlusive vasculitis, or ROV, reported in people receiving injections of Syfovre.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： A new House health package & hospitals’ new site

focus

hotspot

entertainment

Microsoft'sheadofresearchPeterLeespeakingatSTATBreakthroughSummitinSanFrancisco.SarahGonzalezforSTAT

WSS

Trump surgeon general acknowledges mistakes during Covid

AstraZeneca chief proposes a novel edit to the drug pricing bill

The (many) problems with a new study criticizing cancer screening

Humana sues Biden admin over Medicare Advantage audit rule

Microsoft's Peter Lee says ChatGPT shouldn't be used for initial diagnosis

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

hotspot

leisure time

focus

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Big Tobacco's 'harm reduction': Is it for real, or a sham?

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

How to save PrEP access — and even expand it

Case highlights the risks of experimental stem cell therapy

Medicare proposal to cover medical devices draws a mixed reaction

Cytokinetics CEO stresses company can launch heart drug on its own

Wildfire smoke exposes gaps in outdoor worker protections

Addiction experts warn against a second 'war on drugs'

focus

Cytokinetics CEO stresses company can launch heart drug on its own

HIV vaccine remains elusive. Immunologists keep trying new ideas

Helping hospitals and community health centers plan for resilience

Trump surgeon general acknowledges mistakes during Covid

Bird flu: Don't repeat Covid's 'health versus the economy' framing

Anxious about a speech? A startup wants you to pop a minty cardiac drug

focus

hotspot

hotspot

entertainment